Abstract
Reply to the Letter to the Editor ‘Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?’ by Abali et al.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have